Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Scientific Sessions

Minority of SIHD patients undergoing PCI meet ISCHEMIA trial criteria

Roshini Claire Anthony, 20210615180001

Only a small fraction of patients with stable ischaemic heart disease (SIHD) who undergo percutaneous coronary intervention (PCI) in the US meet the inclusion criteria of the ISCHEMIA* trial, according to results of a study presented at SCAI 2021.

Robotic PCI shows high success rates in real-world setting

Elaine Soliven, 20210527000000

A robotic-assisted percutaneous coronary intervention (PCI) approach showed high clinical and technical success rates across all degrees of lesion complexity among patients with coronary artery disease (CAD), according to the final results of the PRECISION GRX* study presented at SCAI 2021.

One-month DAPT sufficient after PCI?

Audrey Abella, 20210524100000

Two separate analyses presented at SCAI 2021 demonstrated that a 1-month dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) appears to be safe and effective for PCI patients at high risk of bleeding (ie, those with advanced age, chronic NSAID use, bleeding history, anaemia, thrombocytopenia, etc), compared with a DAPT regimen between 6 and 12 months.

Long-term DAPT should remain SoC post-PCI in high-risk ACS patients

Roshini Claire Anthony, 20210520180001

Dual antiplatelet therapy (DAPT) for >12 months should remain the standard of care (SoC) for high-risk patients with acute coronary syndrome (ACS) who have undergone percutaneous coronary intervention (PCI), suggested a study presented at SCAI 2021.